Citadel Advisors LLC bought a new position in IO Biotech, Inc. (NASDAQ:IOBT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 270,504 shares of the company's stock, valued at approximately $249,000. Citadel Advisors LLC owned about 0.41% of IO Biotech at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in shares of IO Biotech in the 4th quarter worth approximately $26,000. Vontobel Holding Ltd. purchased a new stake in IO Biotech in the fourth quarter worth $30,000. Renaissance Technologies LLC boosted its holdings in IO Biotech by 22.5% in the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after acquiring an additional 21,800 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in IO Biotech in the fourth quarter valued at $407,000. Finally, Dauntless Investment Group LLC purchased a new position in IO Biotech during the 4th quarter valued at $688,000. Hedge funds and other institutional investors own 54.76% of the company's stock.
IO Biotech Stock Performance
Shares of NASDAQ IOBT traded down $0.07 during mid-day trading on Tuesday, hitting $1.48. 178,441 shares of the stock traded hands, compared to its average volume of 280,838. The company has a market cap of $97.50 million, a price-to-earnings ratio of -1.08 and a beta of 0.36. The stock has a fifty day moving average price of $1.07 and a 200-day moving average price of $0.97. IO Biotech, Inc. has a 52 week low of $0.66 and a 52 week high of $1.73.
Analysts Set New Price Targets
IOBT has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of IO Biotech in a research report on Wednesday, May 14th. Piper Sandler upgraded shares of IO Biotech to a "strong-buy" rating in a report on Wednesday, March 12th.
View Our Latest Stock Analysis on IOBT
About IO Biotech
(
Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
